Nephrotic syndrome

Reading Document
Medical Text Search

nephrotic syndrome etiology pathophysiology clinical features diagnosis

Medical Text Search

nephrotic syndrome management treatment complications

Medical Image Search

nephrotic syndrome histology glomerulonephritis

GradeResponse
GradeResponse
GradeResponse
Here is a comprehensive overview of nephrotic syndrome:

Nephrotic Syndrome

Definition

Nephrotic syndrome (NS) is defined by the triad of:
  • Proteinuria >3.5 g/day (or >3.5 g/1.73 m²/day)
  • Hypoalbuminemia (<3.5 g/dL)
  • Edema
Frequently accompanied by hyperlipidemia (high LDL, low HDL) and lipiduria (Harrison's, p. 8392).

Etiology

Primary (Idiopathic) Glomerulopathies

DiseaseKey FeatureCommon Age
Minimal Change Disease (MCD)No light microscopy changes; effacement of foot processes on EMChildren (most common)
Focal Segmental Glomerulosclerosis (FSGS)Segmental scarring of glomeruliAdults; African Americans
Membranous NephropathySubepithelial immune deposits; "spike and dome" on EMAdults (most common primary NS in adults)
Membranoproliferative GN (MPGN)Mesangial proliferation + GBM thickeningAdolescents/young adults

Secondary Causes

  • Diabetes mellitus — diabetic nephropathy (most common secondary cause worldwide)
  • Systemic lupus erythematosus (SLE) — lupus nephritis (especially class V)
  • Amyloidosis — AL or AA type
  • Infections — HBV, HCV, HIV, malaria, syphilis
  • Drugs — NSAIDs, gold, penicillamine, heroin
  • Malignancy — solid tumors (membranous), lymphoma (MCD)
  • Preeclampsia

Pathophysiology

  1. Glomerular injury → loss of the glomerular filtration barrier (charge and/or size selectivity)
  2. Massive proteinuria (especially albumin) → hypoalbuminemia
  3. Reduced oncotic pressure → fluid shifts into interstitium → edema
  4. Compensatory hepatic lipoprotein synthesishyperlipidemia
  5. Loss of lipoproteins in urinelipiduria
  6. Loss of regulatory proteins → hypercoagulable state (loss of antithrombin III, proteins C and S), increased infection risk (loss of IgG, complement factors), thyroid/endocrine abnormalities

Clinical Features

FeatureDescription
EdemaPeriorbital (especially morning), pedal, ascites, pleural effusion
Frothy urineDue to heavy proteinuria
PallorFrom edema/anemia
Signs of complicationsDVT/PE, infections, cushingoid features (if on steroids)
Urinalysis findings:
  • Heavy proteinuria (3–4+ on dipstick)
  • Oval fat bodies — large tubular epithelial cells engulfed with lipid
  • Maltese crosses under polarized light (cholesterol monohydrate crystals)
  • Fatty casts

Diagnosis

Initial Workup

  1. Urine dipstick + microscopy — proteinuria, oval fat bodies, fatty casts
  2. Spot urine protein:creatinine ratio — >3.5 mg/mg indicates nephrotic-range proteinuria
  3. 24-hour urine protein — gold standard (>3.5 g/day)
  4. Serum albumin, lipid panel, BMP/CMP
  5. Secondary cause workup: ANA, anti-dsDNA, complement (C3/C4), hepatitis B/C serology, HIV, HbA1c, serum protein electrophoresis, cryoglobulins

Kidney Biopsy

Indicated in adults with NS of unclear etiology. Not routinely done in children (MCD presumed and treated empirically with steroids).
Histological patterns:
  • Light microscopy (LM) — MCD appears normal; FSGS shows segmental sclerosis; membranous shows GBM thickening
  • Immunofluorescence (IF) — granular IgG + C3 deposits in membranous; "full house" in lupus
  • Electron microscopy (EM) — foot process effacement (all causes), subepithelial deposits (membranous), mesangial deposits (IgA/lupus)

Management

Disease-Specific Therapy

(Harrison's, p. 8592)
CauseTreatment
MCDPrednisone (first-line); cyclophosphamide or calcineurin inhibitors for frequent relapse
FSGSHigh-dose steroids; tacrolimus/cyclosporine for steroid-resistant
MembranousConservative first; rituximab (now preferred); cyclophosphamide + steroids (Ponticelli)
Diabetic nephropathyACE inhibitor/ARB; SGLT-2 inhibitors; glycemic control
Lupus nephritisMycophenolate mofetil + steroids; belimumab/voclosporin for resistant disease

Supportive Therapy (All Patients)

  1. Edema — sodium restriction (<2 g/day); loop diuretics (furosemide); avoid aggressive diuresis (risk of intravascular depletion)
  2. Hyperlipidemia — statins (HMG-CoA reductase inhibitors); all patients with hypercholesterolemia secondary to NS should be treated due to elevated cardiovascular risk (Harrison's, p. 8592)
  3. Proteinuria reduction — ACE inhibitors or ARBs (reduce intraglomerular pressure and proteinuria, independently of BP)
  4. Anticoagulation — for venous thromboembolism prophylaxis/treatment; serum albumin <2.5 g/dL is a major risk factor, especially in membranous nephropathy
  5. Infection prevention — pneumococcal vaccine; immunoglobulin replacement in refractory cases

Complications

ComplicationMechanism
Thromboembolic events (DVT, PE, renal vein thrombosis)Loss of antithrombin III, protein C/S; platelet hyperactivation
Infections (peritonitis, cellulitis, sepsis)Loss of IgG and complement (opsonins); edema as culture medium
Acute kidney injuryHypovolemia from aggressive diuresis; bilateral renal vein thrombosis
Dyslipidemia / accelerated atherosclerosisIncreased hepatic VLDL synthesis; decreased lipoprotein lipase activity
Endocrine abnormalitiesLoss of thyroid-binding globulin → low total T4 (free T4 normal)
Vitamin D deficiencyLoss of vitamin D-binding protein
Protein malnutritionOngoing urinary protein losses

Nephrotic vs. Nephritic Syndrome

FeatureNephroticNephritic
Proteinuria>3.5 g/day<3.5 g/day (mild-moderate)
HematuriaAbsent or minimalProminent (RBC casts)
HypertensionMild or absentCommon
EdemaMarkedMild-moderate
Serum complementNormal (except MPGN, lupus)Often low
Renal functionUsually preserved initiallyOften reduced

Prognosis

Depends heavily on the underlying cause:
  • MCD: Excellent — >90% respond to steroids; tendency to relapse in children
  • Membranous: ~30% spontaneous remission; ~30% progress to ESRD; rituximab improves outcomes
  • FSGS: Poor without treatment; high rate of progression to ESRD, especially steroid-resistant forms
  • Diabetic nephropathy: Progressive without aggressive management; SGLT-2 inhibitors (empagliflozin, dapagliflozin) have changed the prognosis significantly
This is a shared conversation. Sign in to Orris to start your own chat.